Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CD300ld regulates tumor immunity

ABSTRACT: CD300ld regulates tumor immunity

PROVIDER: PRJNA820780 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18506528_1.fastq.gz	Fastqsanger.gz
	SRR18506528_2.fastq.gz	Fastqsanger.gz
	SRR18506529_1.fastq.gz	Fastqsanger.gz
	SRR18506529_2.fastq.gz	Fastqsanger.gz
	SRR18506530_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Endothelial Fat4 regulates tumor angiogenesis and tumor immunity

Project description:Endothelial Fat4 regulates tumor angiogenesis and tumor immunity

| PRJNA1381626 | ENA

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunity

Project description:Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunity

| PRJNA948416 | ENA

Gut-Brain Axis Regulates Liver Anti-Tumor Immunity

Project description:Gut-Brain Axis Regulates Liver Anti-Tumor Immunity

| PRJNA1065314 | ENA

CD300ld regulates tumor immunity - In vivo Crispr-Cas9 screening

Project description:CD300ld regulates tumor immunity - In vivo Crispr-Cas9 screening

| PRJNA820786 | ENA

Endothelial Fat4 regulates tumor angiogenesis and tumor immunity

Project description:The atypical cadherin FAT4 has mainly been studied as a tumor suppressor, but a pan-cancer analysis of its expression in human tumors suggests this view is likely oversimplified. Here, we identify that across multiple cancer types, FAT4 expression was enriched in cancer patients with high angiogenic activity and low T-cell immunity signatures and was predominantly observed in tumor endothelial cells. Consistently, endothelial Fat4 is required for both retinal and tumor angiogenesis in preclinical mouse models. Mechanistically, FAT4 governs endothelial planar cell polarity (PCP), which is essential for coordinated sprouting and vessel patterning. Strikingly, loss of endothelial FAT4 normalizes tumor vessels, enhances tumor immunity and responsiveness to immune checkpoint blockade, suggesting that targeting FAT4 can overcome endothelial cell anergy and restore anti-tumor immunity. These findings reposition FAT4 as a regulator that links angiogenesis to tumor immunity and extend its function beyond a tumor-cell-intrinsic suppressor. Targeting this pathway may offer an opportunity to normalize tumor vasculature and enhance immunotherapy, but its clinical success will hinge on recognizing the distinct and context-dependent roles of FAT4 in tumor cells and within the tumor microenvironment.

2026-03-02 | GSE313815 | GEO

PRMT1 suppresses anti-tumor immunity

Project description:PRMT1 suppresses anti-tumor immunity

| PRJNA840921 | ENA

Asparagine regulates RIG-I stability to suppress anti-tumor immunity in bladder cancer

Project description:Asparagine regulates RIG-I stability to suppress anti-tumor immunity in bladder cancer

| PRJNA1126245 | ENA

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

Project description:Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

| PRJNA981474 | ENA

Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma

Project description:Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma